Todayâ€™s positive opinion marks an important step in our efforts to bring ULTOMIRIS to the aHUS patient community, where we believe it has the potential to become the new standard of care for this devastating disease."The U.S. Food and Drug Administration (FDA) approved ULTOMIRIS (ravulizumab-cwvz) for the treatment of aHUS to inhibit TMA for adult and pediatric (one month of age and older) patients in October 2019.